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Abstract
In an earlier study we demonstrated that hydroxyapatite nanoparticles coated with chitosan-
poly(D,L)-lactide-co-glycolide (HAp/Ch-PLGA) target lungs following their intravenous injection 
into mice. In this study we utilize an emulsification process and freeze drying to load the 
composite HAp/Ch-PLGA particles with 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate 
(A), a chemotherapeutic derivative of androstane and a novel compound with a selective 
anticancer activity against lung cancer cells. 1H NMR and 13C NMR techniques confirmed the 
intact structure of the derivative A following its entrapment within HAp/Ch-PLGA particles. The 
thermogravimetric and differential thermal analyses coupled with mass spectrometry were used to 
assess the thermal degradation products and properties of A-loaded HAp/Ch-PLGA. The loading 
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efficiency, as indicated by the comparison of enthalpies of phase transitions in pure A and A-
loaded HAp/Ch-PLGA, equaled 7.47 wt.%. The release of A from HAp/Ch-PLGA was sustained, 
neither exhibiting a burst release nor plateauing after three weeks. Atomic force microscopy and 
particle size distribution analyses were used to confirm that the particles were spherical with a 
uniform size distribution of d50 = 168 nm. In vitro cytotoxicity testing of A-loaded HAp/Ch-
PLGA using MTT and trypan blue dye exclusion assays demonstrated that the particles were 
cytotoxic to the A549 human lung carcinoma cell line (46±2%), while simultaneously preserving 
high viability (83±3%) of regular MRC5 human lung fibroblasts and causing no harm to primary 
mouse lung fibroblasts. In conclusion, composite A-loaded HAp/Ch-PLGA particles could be seen 
as promising drug delivery platforms for selective cancer therapies, targeting malignant cells for 
destruction, while having a significantly lesser cytotoxic effect on the healthy cells.
Graphical abstract
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1. Introduction
The potential for application of synthetic calcium phosphates, especially hydroxyapatite 
(HAp), has become intensely broadened in the past 15 years. It has extended from bone 
tissue engineering to multiple other fields of biomedicine, e.g., controlled drug delivery, 
bioactive coatings, gene therapies, wound healing and beyond [1–3]. The enhancement of 
the properties of HAp in this pursuit of new areas of application has progressed in two major 
directions: (a) chemical modification and (b) combination with other materials, 
predominantly polymers. As far as the first direction is concerned, HAp surpasses other 
biominerals in terms of the capacity to incorporate foreign ions, some of which can be 
utilized for therapeutic purposes, substituting the role of costlier biomolecules and 
minimizing the side effects frequently associated with their use [4]. To that end, tailoring of 
the chemical structure of HAp has been achieved through the substitution of its constitutive 
ions (Ca2+, PO43− and OH−) with ions such as Mg2+, Zn2+, Cd2+, Y3+, Mn2+, Ni2+, 
carbonate, selenite, silicate, etc. [5, 6]. Cobalt-substituted HAp, for example, accelerated the 
process of osseointegration after the reconstruction of bone defects in vivo [7].
Progress in the field of composite nanoparticle synthesis has, on the other hand, enabled the 
fabrication of a large number of hybrid, multicomponent systems containing HAp. 
Biocompatible polymeric coatings around HAp nanoparticles have allowed for the 
development of multifunctional nanosystems as carriers of vitamins, antibiotics and genes 
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[8–13]. The tailoring of the structure of multifunctional nanoparticulate drug carriers is an 
emerging branch of research, with the goal of enhancing their biocompatibility and 
therapeutic efficacy [9, 14]. Multifunctional systems exhibit a more convoluted behavior in 
the course of in vitro and in vivo testing and also demand more versatile techniques for their 
physicochemical characterization [14]. Nanostructured HAp has been extensively used in the 
reconstruction of boney tissues and it has also showed promising results as a system with a 
targeted activity in the treatment of osteosarcoma metastases [15]. HAp nanoparticles can 
slow down the growth of various cancer cells, particularly human glioma cells [16]. Organ-
targeting or tumor-targeting via drug-loaded nanoparticles demonstrated their ability to act 
on specific receptors [17]. The targeting of receptors by HAp nanocrystals was proposed as 
the basis for the utilization of HAp doped with rare earth elements for noninvasive medical 
imaging at the molecular level [18]. Our previous research on nano/micro-particle systems 
composed of HAp coated with the chitosan-poly(D,L)-lactide-co-glycolide polymer blend 
(HAp/Ch-PLGA) has justified the use of HAp as a core component of composite drug 
carriers for organ-targeting therapies [19]. Along with the particle size, shape and 
composition, the fate of particles injected into the bloodstream is mainly defined by the type 
and the structure of proteins bound to them [20, 21], which can be controlled by tailoring the 
composition, the topography and the charge distribution on the particle surface. Coating 
HAp nanoparticles with different polymers has correspondingly directed HAp to different 
organs [19]. Specifically, unlike pure HAp and HAp coated with PLGA only, which were 
being accumulated in liver, spleen and kidneys, HAp/Ch-PLGA particles were 
overwhelmingly localizing in the lungs of mice following the intravenous injection of the 
particulate dispersion [19]. Bone defect reparations have been successfully performed using 
nanoparticulate systems based on PLGA-coated HAp, providing a rationale for the 
consideration of PLGA as a coating for organ-targeting delivery systems [10–12]. One of the 
advantages of mixing PLGA with chitosan within nanoparticulate platforms for controlled 
delivery of chemotherapeutics in the treatment of cancer is an improved permeation of the 
cell membrane [22]. The enhanced sialylation of malignant cells [23] benefits the idea of 
using cationic Ch to target cancer cells and may be the reason behind its occasionally 
observed anticancer properties [24]. The previously observed ability of the positively 
charged molecules and particles to localize in lungs [25–28] may also be a key to explaining 
the pronounced lung-targeting potential of HAp/Ch-PLGA particles [19].
Lung cancer is the leading cause of cancer mortality [29]. Estrogen and progesterone are 
hormones that play an important role in the carcinogenesis of lung cells [30], placing this 
type of cancer in the category of hormone-dependent cancers. The 17-picolyl, 17-
picolinylidene, 17-picolinylidene-16-one and 17-picolyl-16-one androstane derivatives are 
effective cell inhibitors of hormone-dependent cancers, e.g., adenocarcinoma, prostate 
cancer, cervix carcinoma, colon cancer, etc. [31–33]. This explains their choice as a 
chemotherapeutic drug to be delivered to lung cancer cells in this study. As for the choice of 
the carrier, HAp nanoparticles have been used with success to target tumors through 
vasculature and extend life expectancy in animal studies. For example, HAp nanoparticles, 
albeit doped with selenite ions and injected into the bloodstream, extended the lifetime of 
mice with hepatocellular carcinoma [34]. Also, a direct injection of HAp nanoparticles into a 
transplanted tumor formed by Bel-7402 human hepatocarcinoma cells in nude mice led to a 
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50 % reduction in the tumor size [35]. On the other hand, the antiproliferative activity of 
HAp was twice more intense for cancer cells than for the normal ones, both in vitro and in 
vivo [35]. The selective cytotoxicity exhibited by HAp was also not due to the release of 
reactive oxygen species [35] (as is the case with, e.g., carbon nanotubes, quantum dots, Ag 
nanoparticles), as this would cause unselective cytotoxicity, targeting both cancerous and 
healthy cells [36]. Rather, nanosized HAp particles get internalized by cancer cells and 
localized around the endoplasmic reticulum (ER), where they presumably interfere with the 
translation process by competing for ribosome binding together with mRNA, thus arresting 
the cell cycle in G0/G1 phase [35]. Interestingly, the androstane derivative chosen as the 
anticancer drug for this study owes its selective anticancer activity to a similar effect, i.e., the 
induction of the ER stress response, resulting in calcium release from the ER and the G1 
phase cycle arrest [37]. Given the similar mechanism by which HAp and the compound A 
inhibit the proliferation of cancer cells, a possible therapeutic synergy between the carrier 
(HAp) and the drug (A) is worth investigating.
In our previous study we demonstrated the ability of nanoparticles composed of HAp coated 
with Ch-PLGA polymer blend to target lungs following intravenous administration [19]. In 
this study we describe the fabrication of androstane (17β-hydroxy-17α-picolyl-androst-5-
en-3β-yl acetate, A)-loaded HAp/Ch-PLGA particles and the assessment of their anticancer 
properties against lung cancer cells. The encapsulation efficiency (EE) and the drug loading 
content (DLC) in multifunctional nanosystems for active or passive targeting are important 
parameters that define not only the structure and the properties of the system, but also its 
application efficiency [38, 39]. In the present study we examine the possibility of using 
differential thermal analysis/thermogravimetric analysis (DTA/TGA) coupled with on-line 
mass spectrometry to obtain direct information on the efficiency of the androstane derivative 
encapsulation. The release of the drug is also assessed, knowing that the drug release 
kinetics defines the effects that the therapy will have on both malignant and healthy cells. 
Needless to add, anticancer drugs are toxic not only to the cancer cells, but also to the 
healthy ones. Designing selective anticancer medicaments, having a high activity toward 
cancer cells but a low activity toward healthy ones, has been an immense challenge in the 
past twenty years [40, 41]. Tools that employ nanotechnologies may be successfully applied 
to address these challenges [42, 43]. In this study we test the comparative cytotoxic response 
of human lung carcinoma (A549) and healthy human lung fibroblasts (MRC5) to their in 
vitro treatment with the A-loaded HAp/Ch-PLGA composite particles. We have also 
analyzed the period of recovery of the two types of cells after their treatment with A-loaded 
HAp/Ch-PLGA.
2. Materials and methods
2.1. Synthesis of 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl acetate-loaded HAp/Ch-PLGA
2.1.1. Synthesis of 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl acetate (A)—
The first stage in the preparation of 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate 
(A) was the addition of α-picolyllithium to the 17-oxo group of dehydroepiandrosterone, 
resulting in 17α-picolyl-androst-5-en-3β,17β-diol. This was followed by the acetylation 
using acetic anhydride in absolute pyridine at room temperature for 3 h [44].
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2.1.2. Synthesis of HAp, HAp/Ch-PLGA and A-HAp/Ch-PLGA—An aqueous 
calcium nitrate (Ca(NO3)2) solution (150 ml; 26.6 wt.%) was added to the solution of 
ammonium phosphate ((NH4)3PO4) (7 ml H3PO4+165 ml NH4OH+228 ml H2O) at 50°C 
over the period of 60 minutes, while stirring at the rate of 100 rpm. The solution was then 
subjected to a heat treatment at 100°C for 60 minutes [45]. The resulting gel was dried at the 
room temperature in a vacuum drier for 72 h, after which the final product - HAp powder - 
was obtained. X-ray diffraction run on the HAp powder confirmed its poorly crystalline 
nature, whereas the PSD technique enabled us to determine the particle size of d50=70 nm 
[19].
Chitosan (Ch) of a low molecular weight (Aldrich, deacetylation > 75%), dissolved in acetic 
acid (1 wt.%), was mixed with 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl acetate powder 
(A) in 2:1 weight ratio while stirring with a magnetic stirrer at 400 rpm. PLGA (50:50, 
Sigma, USA) dissolved in acetone was mixed with the A-containing Ch solution and HAp 
gel in 2:3:5 weight ratio. A water solution of poloxamer 188 (polyethylenepolypropylene 
glycol, 0.1 vol.%) was added dropwise to the resulting mixture, while stirring at 21,000 rpm. 
The obtained mixture of A, chitosan, PLGA and HAp was slowly poured into a 
glutaraldehyde solution (Grade I, 25% in H2O), while stirring at 21,000 rpm for 1 h. The 
obtained mixture was then centrifuged at 3000 rpm and 5°C for 1 h, and the resulting 
precipitate was subjected to lyophilization at temperatures ranging from −10 to −60°C and 
pressures ranging from 0.37 mbar to 0.1 mbar for 1 to 8h [19, 46]. The obtained powder was 
washed with distilled water twice, centrifuged at 1000 rpm and dried again. The final 
product was a powder composed of HAp particles coated with A-loaded chitosan-poly(D,L)-
lactide-co-glycolide (A-HAp/Ch-PLGA). The weight ratio of HAp:Ch:PLGA:A components 
was 5:2:2:1.
2.2. Characterization
NMR spectra were recorded on a Bruker AVANCE III HD 400 spectrometer operated at 400 
MHz (1H) and 100 MHz (13C), and are reported in ppm downfield from the 
tetramethylsilane internal standard. A thermal analysis was simultaneously performed using 
a Thermo-Gravimetric Analysis/Differential-Thermal Analysis (TGA/DTA), SETSYS 2400 
CS Evolution (Setaram Instrumentation) coupled with a mass spectrometric (MS) gas 
analysis system (Omni Star, Pfeiffer). Samples containing 10±0.5 mg were analyzed in air 
by heating (10°C/min) from 28°C to 600°C. Differential scanning calorimetry (DSC) 
measurements were performed on an Evo 131 (Setaram Instrumentation) differential 
scanning calorimeter. Samples containing 10±0.5 mg were analyzed in nitrogen by heating 
(10°C/min) from 25°C to 360°C. Infrared spectroscopy (FT-IR) was done on an Micro-FT-
IR Nicolet iN10 with a DTGS room T detector (Thermo Scientific Instruments), using the 
KBr technique in the spectral range from 400 to 4000 cm−1. The particle size distribution 
(PSD) was measured on 10 mg/mL of powders dispersed in water using a Mastersizer 2000 
(Malvern Instruments Ltd.) and a HydroS dispersion unit for liquid dispersants. 
Microstructural characterization was performed using an atomic force microscope (AFM, 
Thermo Microscopes, Autoprobe CP Research). Zeta potential of the particles in suspension 
was measured in the 1.5–13 pH range on a Zetasizer Nano-ZS (Malvern) dynamic light 
scattering (DLS) device. Drug release experiments were performed by placing the powder in 
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50 ml phosphate buffered saline (PBS) in closed conical tubes and incubating at 37°C and 
50 rpm for up to three weeks. To estimate the concentration of the released drug, aliquoted 
solutions were analyzed in duplicates for absorbance on a UV/Vis spectrophotometer 
(Nanodrop 2000, Thermo Scientific) at λ=263 nm.
2.3 Cell culture
Cytotoxicity assays were performed using two cell lines, human lung carcinoma (A549 
ATCC CCL 185) and human lung fibroblasts (MRC-5 ATCC CCL 171) in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco BRL, UK) with 4.5g/l glucose, 10% FBS (fetal 
bovine serum, Sigma) and containing penicillin(100I.U./ml) and streptomycin (100μg/ml). 
The cell lines were grown at 37°C and in air containing 5 % CO2 (Heracus). The cells were 
passaged twice a week; those used in the experiments were in the log phase of growth 
between the third and the tenth passage. Only the viable cells were used. The number of 
cells and their viability were determined using the dye exclusion test with 0.1% trypan blue.
2.3.1. Trypan blue dye exclusion assay—Cells were seeded at 2×105 cells/ml in 24 
well plates (Center well, Falcon), on top of a film made of compressed A-HAp/Ch-PLGA 
particles and the total concentration of the solid phase equaling 17.6±0.4 mg/ml, i.e., 
46.3±1.0 mg/cm2. After the incubation period of 48 hours, the cells were trypsinized, 
centrifuged at 200 g for 10 minutes and resuspended in DMEM. Ten μl of the cell 
suspension were removed and mixed with an equal amount of 0.1% trypan blue. Ten μl of 
the cell/trypan blue solution were pipetted onto a hemocytometer and live cells were counted 
using an inverted light microscope (REICHERT). Cytotoxicity was expressed in percentages 
according to the following formula: CI=(1−Ns/Nk)×100%, where Nk was the average 
number of cells in the control samples, and Ns was the average number of cells in the 
samples containing the examined substance. All the samples for the dye exclusion test were 
analyzed in quadruplicates.
2.3.2. MTT cell viability assay—Both lung carcinoma cells and fibroblasts were plated 
at 2×105 cells/well in a 96-well microtiter plate (Falcon) and grown on top of a film made of 
compressed HAp/Ch-PLGA or A-HAp/Ch-PLGA particles and the total concentration of the 
solid phase equaling 17.6±0.4 mg/ml, i.e., 46.3±1.0 mg/cm2. After 48 hours, the MTT 
reagent was added into all the wells and incubated for 3 hours at 37°C. After 3 hours, 100 μl 
of 0.04 mol/l HCl in isopropanol were added to each well. Absorbance was read 
immediately using a microtiter plate reader (Multiscan, MCC/340) at the wavelength of 540 
nm and the reference wavelength of 690 nm. Cytotoxicity was expressed in percentages 
according to the formula: CI=(1−As/Ak)×100%, where Ak was the average absorbance of 
the control samples and As was the average absorbance of the samples containing the 
examined substance. All the samples for the colorimetric viability test were analyzed in 
quadruplicates.
2.3.3. Immunofluorescent staining—Primary mouse lung fibroblasts were isolated 
from 9-week old C57BL/6 mice. Fibroblasts were grown in DMEM with 10% fetal bovine 
serum and 5% antibiotic (penicillin/streptomycin) and antimycotic (fungazone). For the 
immunofluorescence analysis, the cells were seeded onto glass coverslips at 1×105 cells per 
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well in a standard 24-well plate and 1 mg/ml of nanoparticles were added in the powder 
form to them and swirled to achieve proper dispersion. In addition to dispersed particles, this 
yielded a moderate amount of particle conglomerates, visually observable in interaction with 
the cells under a fluorescent optical microscope. Cells were allowed to grow in conjunction 
with the particles for 4 days at 37°C, 5% CO2. On Day 4, the cells were fixed in 4% 
paraformaldehyde for 5 minutes, washed thrice in PBS, for 5 minutes each, and stained with 
Alexa Fluor 568 rhodamine-phalloidin (1:400) for 30 minutes. After staining, the cells were 
washed thrice, for 5 minutes each, in PBS and incubated for 25 minutes with NucBlue Fixed 
Cell Ready probe reagent. Cells were then rinsed thrice with PBS, for 5 minutes each, and 
the coverslips with cells were mounted onto microscope glass slides using Prolong Diamond 
and cured overnight. Images were acquired on a Zeiss LSM 710 confocal microscope (UIC 
core imaging facility).
3. Results and discussion
3.1. 1H NMR and 13C NMR analyses of 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl acetate 
(A)
In the 1H NMR spectra of the androstane derivative (Fig. 1a), compound A, the signals from 
protons from the heterocyclic ring at C-17 position were detected with a downfield shift, in 
the 7.20–8.47 ppm range, as a result of the deshielding influence of the nitrogen atom. Two 
protons from C-20 methylene group were registered at 2.84 and 3.11 ppm. The 13C NMR 
spectral signals (Fig. 1b) were assigned to carbons from the heterocyclic ring at 122.38, 
124.91, 137.00, 147.78 and 160.75 ppm. As expected, the signal from 3-acetoxy group of 
the compound A was detected in 1H NMR spectra at 2.05 ppm. The corresponding relatively 
intense 13C NMR signals were observed at 21.46 and 170.60 ppm for methyl and carbonyl 
atoms from the 3-acetoxy group, respectively.
3.2. Differential-Thermal Analysis (DTA)
The DTA thermograms of HAp, Ch, PLGA, A and A-HAp/Ch-PLGA in the temperature 
range of 25–600°C are shown in Figure 2. In contrast to the one-step thermal degradation of 
chitin, the thermal degradation of chitosan is characterized by a two-step process entailed by 
chain scission and repolymerization reactions [47]. After the evaporation of the surface-
bound water, yielding the broad endothermic peak at 100°C (Fig. 2a.), one may notice a 
narrow endothermic peak in the 306–320°C interval. As in agreement with previous 
findings, this thermal event derives from the degradation and deacetylation of chitosan [48] 
and the formation of vaporous fragments with a lower molecular weight, including char [47]. 
A sequence of endothermic peaks in the DTA thermogram of PLGA (Fig. 2a) at 
temperatures between 328°C and 342°C, as well as two major peaks centered at 364°C and 
390°C, originate from the decomposition of the polymer. The decomposition of PLGA at 
temperatures around 360°C has also been observed by other authors [49]. The suggested 
mechanism for the thermal degradation of PLGA is based on an interaction between the end 
hydroxyl groups of the polymeric chains and the resulting formation of cyclic oligomers, 
lactides, acetaldehydes, methyl glycolates and carbon monoxide. At higher temperatures, the 
release of carbon dioxide, methyl ketene or formaldehyde occurs [50, 51].
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As seen in Fig. 2b, the DTA thermogram of A-loaded HAp/Ch-PLGA is dominated by peaks 
characteristic for the pure compound A. The two most prominent endothermic peaks of the 
compound A, at 204 and 330°C (zone I and II in Fig. 2b, respectively), are detected in A-
loaded HAp/Ch-PLGA too. The sequence of endothermic peaks originating from the 
degradation PLGA is observed at the higher temperature end of the 330°C peak exhibited by 
the compound A. The major one of these peaks exhibits a shift to lower temperatures, from 
365 to 340°C, following the combination of PLGA with HAp in composite HAp/Ch-PLGA, 
suggesting the surface presence of the polymeric phase in a thinner form, more exposed to 
the atmospheric heat than the bulkier, pure PLGA particles, thus requiring lesser heat to 
reach their interior and initiate the degradation process. The semblance of the two 
thermograms presented in Fig. 2b unequivocally indicates that the method for the 
encapsulation of the compound A into HAp/Ch-PLGA (section 2.1.1) preserves its native 
structure.
3.3. TG-MS Gas Analysis
A comparative overview of thermogravimetric (TG) diagrams and the corresponding MS 
spectra of the gas product analysis of the A-loaded HAp/Ch-PLGA composite and of its four 
individual components are shown in Figure 3. The TGA curve of HAp demonstrates a total 
weight loss of about 7% at 600°C [52], being solely due to the evaporation of physically 
adsorbed water, which, as seen from the corresponding mass spectrogram, is completed by 
the point the system reaches about 250°C. This observed water loss, centered at around 
100°C, agrees with the results of the DT analysis (Fig. 2a).
The moderate weight loss of chitosan (Fig. 3a) up to about 250°C is associated with the loss 
of adsorbed water. In the subsequent 250–600°C interval, the region extending from 250°C 
to 300°C stands out with a drastic weight decrease: from 86% to 55%. It is followed by the 
region extending from 300°C to 450°C, where a milder weight loss is observed, from 55% to 
30%, and then the region extending from 450 to 600°C, where the weight drops from 30% 
down to only 0.6%. Similar TGA results for chitosan have been reported by others as well 
[53, 54]. A dramatic chitosan weight loss in the 306–320°C temperature interval due to 
deacetylation (Fig. 2a) is confirmed by the increasing CH3COOH concentration in the MS 
gas analysis. The release of H2O, CO, CO2 and CH3COOH in the 280–500°C temperature 
interval has also been confirmed by other authors by means of FT-IR analyses [53]. In the 
temperature interval between 260 and 400°C, a sudden drop in the PLGA weight occurs 
(Fig. 3b) and a complete degradation takes place at temperatures higher than 400°C. 
According to the thermogravimetric analyses of PLGA reported earlier, the pyrolysis of 
PLGA was detected at temperatures as low as 255°C, whereas its full degradation occurred 
at temperatures extending from 400°C upwards [49, 55]. In the 260°C–400°C interval, the 
significant PLGA weight loss is accompanied by the maximal contents of CO2, H2O and 
CH3COOH in the MS gas analysis. Physicochemical phenomena caused by heating the 
compound A to 600°C were reflected in 98.71 % total weight loss (Fig. 3c). Detected in the 
428–528°C interval, the dissociation of benzene from the rest of the molecule, typical for the 
MS spectrum of the compound A, indicates the fragmentation of its structure. The TGA 
curve for A-HAp/Ch-PLGA shown in Figure 3d demonstrates a 56.63 % weight loss at 
600°C. The remaining 43.37 % of weight contains only HAp and the compound A, given 
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that the weight ratio of Ch and PLGA at this final stage of the heating process is 0% due to 
their complete thermal degradation. Every single MS spectrum of the individual constituents 
of the composite system - HAp, Ch, PLGA and the derivative A - is present in the MS 
spectrum of A-HAp/Ch-PLGA, which, together with the DTA results, confirms the 
successful encapsulation of the derivative A.
3.4. Fourier transform infrared spectroscopy (FT-IR) analysis of A and A-HAp/Ch-PLGA
In order to additionally confirm the qualitative content of A-HAp/Ch-PLGA, the material 
was analyzed using FT-IR spectroscopy. The IR spectra of the compound A and of A-
HAp/Ch-PLGA composite particles are shown in Fig. 4a. The wide IR band in the spectrum 
of A (17β-hydroxy-17α-picolyl-androst-5-en-3β-yl acetate), with the maximum at 3303 
cm−1, is assigned to the O-H stretch (17β-OH). Several absorption bands with maxima at 
2943 and 2827 cm−1 originate from the alkyl stretches of the C–H group (−CH3 and =CH2). 
The valence vibrations of the acetate group were observed as a sharp band with the 
maximum at 1246 cm−1.
The IR spectrum of A-HAp/Ch-PLGA is additionally characterized by the absorption bands 
arising from HAp, Ch and PLGA: ν(OH) 3600–3000 cm−1 (HAp, PLGA, Ch; intensive, 
wide band), ν(C=O) 1750 cm−1 (PLGA; strong intensity), ν(C=O) 1655 cm−1 (amide I 
band, Ch; strong intensity), δ(HOH) approx. 1640 cm−1 (HAp, PLGA, Ch; weak to medium 
intensity), δsy(CH) 1380 and δas(CH) 1450 cm−1 (HAp, PLGA, Ch; weak to medium 
intensity), δ(OH) 1420 cm−1 (HAp, PLGA, Ch; medium intensity), ν(P=O) 1090 cm−1 
(HAp; strong intensity), ν(P–O) 1025 cm−1 (HAp; strong intensity overlapped with a band 
ν(P=O)), δ(CH) and δ(OH) 1000–700 cm−1 (HAp, PLGA, Ch; weak intensity) [19, 45]. The 
existence of the absorption bands originating exclusively from the compound A in the IR 
spectrum of A-HAp/Ch-PLGA confirms that the substance was entrapped inside the 
composite particles. Specifically, the group of absorption bands with maxima at about 2943 
and 2827 cm−1 (C–H group from −CH3 and =CH2), =C=O with the maximum at around 
1727 cm−1, as well as the valence vibrations of the acetate group at 1246 cm−1 indicate the 
presence of A in A-HAp/Ch-PLGA.
The cross-linking of chitosan (Ch) by glutaraldehyde (GA) is a complex process, typically 
leading to inhomogeneous products [56]. Mechanistically, free pendant amine groups of 
chitosan react with the aldehydic group of GA and yield imine bonds [57], distinguishable as 
the 1600 cm−1 peak in the corresponding IR spectra and originating from the stretching 
vibration of the imine C=N bond [58]. This peak was observed in Ch hydrogels formed in a 
range of different Ch:GA weight ratios (16:1 to 1:1) [59], while the Ch:GA reaction is 
reported to reach equilibrium at Ch:GA = 1:1 conditions [57]. In this study we used GA as a 
cross-linker to a fivefold amount compared to the content of Ch (Ch:GA = 5:1). The 
appearance of a new peak following the initiation of the cross-linking reaction at 1600 cm−1 
(Fig. 4a) indicates that the cross-linking occurred in the system.
3.5. Particle size distribution and AFM analysis of A-HAp/Ch-PLGA
The morphology and the size distribution of particles constituting A-HAp/Ch-PLGA 
powders are shown in Figure 4b. The particles had a uniform distribution of sizes, with the 
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d50 parameter equaling 168 nm. The composite powder contained a small portion of larger 
and smaller particles; correspondingly, d90=247 nm and d10=135 nm. The surface 
morphology of A-HAp/Ch-PLGA, analyzed using AFM in a non-contact mode (Fig. 4b), 
was dominated by oval topographic features, originating from the spherical shape of the 
individual particles. The coating of nanoparticles of HAp (d50=70 nm) with A-loaded Ch-
PLGA in the centrifugal field (section 2.1.2.) yielded spherical particles of a highly similar 
size and shape as those obtained in our earlier study on the synthesis of A-free HAp/Ch-
PLGA [46].
3.6 Differential scanning calorimetry (DSC) and the drug release from A-HAp/Ch-PLGA
Figure 5a shows DSC thermograms of the derivative A and of A-HAp/Ch-PLGA. The 
endothermic phase transformation observed in the DT analysis of A at 204°C (Fig. 2b) 
dominates the DSC thermogram with a sharp peak centered at 213.82°C (onset 211.44°C, 
offset 415.46°C). The same phase transition is noticeable on the thermogram of A-HAp/Ch-
PLGA, next to (a) the broad endothermic doublet (onset 53.62°C, offset 131.52°C) 
corresponding to PLGA and Ch transformations, and (b) the wide exothermic peak 
corresponding to deacetylation of Ch (onset 290.86°C, offset 312.40°C). The integration of 
the area under the endothermic peaks paralleling the phase transitions characteristic for the 
pure and the encapsulated derivative A yielded enthalpy (ΔH) values of 69.704 and 5.207J/g, 
respectively. Based on the comparison of ΔH for the pure and the encapsulated A, the 
content of the encapsulated derivative A in A-HAp/Ch-PLGA could be estimated at 7.47 wt.
%. Out of the projected drug content of 10 wt.% (sec 2.1.1.), 7.47 wt.% was achieved. The 
calorimetric method involving the measurement of the enthalpy of the phase transition 
associated with the melting of the drug within the carrier has been used with success to 
predict the loading capacity of poorly water-soluble drugs, the category to which the 
compound A belongs too [60].
One of the benefits of polymeric carriers capable of entrapping the hydrophobic drug 
internally comes from the extension of its therapeutic half-life by preventing the aggregation 
of the free drug due to hydrophobic forces. Another advantage comes from the sustained 
release profile, thanks to which the concentration of the drug in the blood and/or the target 
tissue could be maintained at the therapeutically active level, avoiding the fluctuations 
between toxic and ineffective levels that are secondary to repetitive intravenous bolus 
administrations. One such sustained release of A from A-HAp/Ch-PLGA is seen in Fig. 5b. 
The release follows a relatively linear pattern, with no burst release or plateauing after three 
weeks of release.
3.7. Zeta potential analysis of HAp/Ch-PLGA and A-HAp/Ch-PLGA particles
At the physiological pH, the zeta potential of A-HAp/Ch-PLGA particles (−8.7±0.5 mV) is 
significantly more negative than that of A-free HAp/Ch-PLGA particles (−2.8±0.8 mV), the 
reason being the masking of a portion of the positively charged amine groups of chitosan by 
the negative charged acetate and hydroxyl groups of A. In contrast, the given hydroxyl and 
acetate groups are more resistant to protonation under acidic conditions (pHs 3.5 and 5.5) 
than the amine groups of chitosan, explaining the greater increase of zeta potential in the 
positive range for HAp/Ch-PLGA than for A-HAp/Ch-PLGA. The isoelectric point of 
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HAp/Ch-PLGA concordantly becomes shifted to lower values, from 6.5 to 5.6, following the 
entrapment of A.
3.8. Selectivity of the in vitro antitumor activity of A-HAp/Ch-PLGA
Derivatization of 17-picolyl androstane presents a promising starting point for the 
development of a new group of compounds for the treatment of cancer. Modified androstane 
derivatives exhibited an antiproliferative activity against several types of human cancer cells, 
including breast, prostate, cervical, colon and lung adenocarcinoma [37, 61]. Here we report 
the parallel assessment of cytotoxicity of the compound A, an androstane derivative, 
delivered using submicron HAp/Ch-PLGA particles as a carrier, on two different cell lines: 
A549 human lung carcinoma cells and regular MRC5 human lung fibroblasts. After the 
incubation with A-HAp/Ch-PLGA for 48h, the viability of the cells measured using the 
trypan blue exclusion test was 83±3% for MRC5 fibroblasts and 65±2% for A549 lung 
carcinoma cells. The viability for both cell lines was lower than for the corresponding 
untreated controls as well as for the cells treated with A-free HAp/Ch-PLGA particles 
(p<0.05), in which case the viability equaled 89±2% for both cell types (data not shown). In 
contrast, cytotoxicity for the MRC5 fibroblasts treated with A-HAp/Ch-PLGA particles was 
17±1%, whereas that for A549 tumor cells was 46±2% (Fig. 6a). Accordingly, the cytotoxic 
effect of A-HAp/Ch-PLGA particles is almost three times greater on the malignant A549 
cell than on the healthy MRC5 fibroblasts. The activity of the pure compound A was equally 
selective as that of A-HAp/Ch-PLGA, given that the viability of A549 and MRC5 cells 
treated with the pure compound A equaled 36 % and 83 %, respectively, at [A] = 100 μM. 
The corresponding IC50 curves are given in the Supplementary Section. When after 48 h of 
incubation with the tested material, A549 and MRC5 cells were left to recover for another 
48 h, the cytotoxicity readings were 23±2% for A549 tumor cells and 11±1% for MRC-5 
cells (Fig. 6b). This is to say that following the treatment with A-HAp/Ch-PLGA particles, 
the malignant cells recovered twice as fast as the healthy ones. This can be explained by the 
different nature of these two cell lines, A549 and MRC5, with the malignant cells being 
more aggressive and proliferating more intensely than the regular fibroblasts [62]. The 
opposite effect, interestingly, is observed for A-free HAp/Ch-PLGA particles, in which case 
A549 cells did not exhibit any recovery in the same period of time (Fig. 6b), as opposed to 
MRC5 cells, which recovered almost completely, with the cytotoxicity dropping down to 
2%. A similarly selective behavior, targeting cancer cells more intensely than the normal 
cells, was previously reported for drug-free HAp nanoparticles [35], the core components of 
composite particles tested in this study.
The immunofluorescent staining of primary fibroblasts interacting with HAp/Ch-PLGA and 
A-HAp/Ch-PLGA particles demonstrated no negative morphological or proliferative effects 
on the cells (Fig. 7). No microfilament granulations were observed, and f-actin fibers assume 
a healthy, striated form in cells in direct contact with both HAp/Ch-PLGA and A-HAp/Ch-
PLGA particles. No repulsion of the particles by the cells, previously observed for specific 
Ch-HAp combinations [63], was observed either. No reduction in the cell density entailed 
the treatment with A-free and A-loaded HAp/Ch-PLGA particles. In fact, the nuclei count 
yielded the cell density of 35×103 cells/cm2 for A-HAp/Ch-PLGA as opposed to 24×103 
cells/cm2 for A-HAp/Ch-PLGA after 4 days of growth, suggesting that the addition of A to 
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HAp/Ch-PLGA exerted a positive proliferative effect on primary fibroblasts. The main 
difference observed between HAp/Ch-PLGA and A-HAp/Ch-PLGA lay in the more 
pronounced uptake of A-free HAp/Ch-PLGA. As seen in Figs. 7c and 7k, a larger number of 
cells display the internalized particles in the population incubated with A-free HAp/Ch-
PLGA. The visually observed reduction in dispersability of HAp/Ch-PLGA following the 
entrapment of A cannot stem from the modified surface charge of the particles because zeta 
potential of A-HAp/Ch-PLGA was higher than that of HAp/Ch-PLGA at the physiological 
pH indicating a lowered surface charge propensity for aggregation following the entrapment 
of the drug. This effect cannot be either due to a difference in the particle size because there 
is virtually none: d50 for HAp/Ch-PLGA is 168 nm and d50 for HAp/Ch-PLGA is 163 nm. 
Both particles also typified by relatively narrowly dispersed spherical morphologies. An 
increase in the hydrophobicity of the particle surface might be responsible for the larger and 
less dispersable particle aggregates in the HAp/Ch-PLGA system containing A.
These data indicate the selectivity with which the androstane derivative A delivered using 
HAp/Ch-PLGA particles imposes higher cytotoxicity on lung tumor cells than on the healthy 
ones. The mechanism by which the given androstane derivative exerts a toxic effect on the 
cancer cells involves the induction of the ER stress response, which results in calcium 
release from the ER and arrest of the cell in the G1 phase cycle [37]. A carrier capable of 
further elevating calcium levels as a result of its degradation in the lysosome, alongside 
localizing itself in the vicinity of the ER, as HAp has been confirmed to do [35], is a logical 
choice for the delivery vehicle for the given drug. Here we see that the therapeutic selectivity 
of the compound A becomes preserved following its delivery by means HAp/Ch-PLGA. In 
vivo delivery and the optimization of the drug/carrier interface will be the subjects of further 
studies.
4. Conclusion
A novel particulate platform for targeting lung cancer and causing the death of cancer cells 
in a selective manner was explored. Particles composed of HAp coated with the chitosan-
poly(D,L)-lactide-co-glycolide (Ch-PLGA) polymer blend, previously shown to localize in 
lungs following their intravenous administration, were loaded with an androstane derivative, 
17β-hydroxy-17α-picolyl-androst-5-en-3β-yl acetate (A). The results of 1H NMR and 13C 
NMR analyses were mutually consistent, confirming the entrapment of the synthesized 
androstane derivative inside HAp/PLGA-Ch particles in a structurally intact form. The 
thermogravimetric and differential thermal analysis coupled with mass spectrometry was 
used to qualitatively confirm the drug loading process. A-HAp/Ch-PLGA particles were 
found to be spherical and had a uniform size distribution of d50=168 nm. By measuring the 
heat flow associated with phase transitions occurring during heating and calculating the 
corresponding enthalpies, the drug content of the derivative A in A-HAp/Ch-PLGA particles 
was estimated at 7.47 wt%.
The results of cytotoxicity and viability assays performed on A549 lung adenocarcinoma 
cells and on healthy MRC5 fibroblasts demonstrated that the particles of hydroxyapatite/
chitosan-poly(D,L)-lactide-co-glycolide loaded with 17β-hydroxy-17α-picolyl-androst-5-
en-3β-yl acetate exhibit almost three times higher cytotoxicity towards the carcinoma cells 
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(A549) than towards the healthy cells (MRC5). At the same time, no negative effects were 
observed on primary lung fibroblasts, indicating the prospect with which this drug delivery 
system could be further explored as a fine particle platform for a targeted and selective 
cancer therapy that would impose minimal side effects on the patient.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Selective anticancer activity of lung-targeting;
• Hydroxyapatite/chitosan-PLGA particles loaded with an cancer 
inhibitor;
• TGA and DTA coupled on-line with MS were used;
• No negative effects were observed on primary lung fibroblasts;
• Drug delivery platforms for selective cancer therapies
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Figure 1. 
Nuclear magnetic resonance (NMR) spectra of 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl 
acetate (A): a) 1H NMR and b) 13C NMR. 1H NMR (CDCl3, δ, ppm): 0.98 (s, 3H, H-18); 
1.07 (s, 3H, H-19); 2.05 (s, 3H, CH3 from A group); 2.84 (d, 1H, Jgem = 14.4 Hz, CH2Py); 
3.11 (d, 1H, Jgem = 14.4 Hz, CH2Py); 4.63 (m, 1H, H-3); 5.40 (d, 1H, J = 4.8 Hz, H-6); 7.20 
(m, 2H, H-3′ i H-5′, Py); 7.66 (t, 1H, J3′,4′ = J4′,5′ = 7.8 Hz, H-4′, Py); 8.47 (d, 1H, J6′,5′ = 
4.8 Hz, H-6′, Py). 13C NMR (CDCl3, δ, ppm): 14.13 (C-18); 19.33 (C-19); 20.75; 21.46 
(CH3 from A group); 23.99; 27.77; 31.84; 32.16; 32.70; 35.97; 36.73; 37.09; 38.12; 43.08; 
46.37; 50.18; 51.06; 73.93 (C-3); 83.52 (C-17); 121.43 (C-6); 122.38 (C-5′, Py); 124.91 
(C-3′, Py); 137.00 (C-4′, Py); 139.80 (C-5); 147.78 (C-6′, Py); 160.75 (C-2′, Py); 170.60 
(C=O from A group).
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Figure 2. 
Differential thermal analysis (DTA) curves for a) HAp, Ch, PLGA and b) A and A-HAp/Ch-
PLGA
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Figure 3. 
Spectra obtained from the thermogravimetric (TG) and mass spectrometric (MS) gas 
analysis of a) Ch, b) PLGA, c) A and d) A-HAp/Ch-PLGA in the 28–600°C temperature 
interval and at the heating rate of 10 °C/min.
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Figure 4. 
IR spectroscopy and morphology of A-HAp/Ch-PLGA. a) FT-IR spectra, b) the particle size 
distribution and 2D AFM image
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Figure 5. 
a) Differential scanning calorimetry (DSC) thermograms of A and A-HAp/Ch-PLGA. b) 
The release of A from A-HAp/Ch-PLGA in PBS at 37 °C over the period of 21 days. Data 
points represent averages (n=2) and the error bars represent standard deviations.
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Figure 6. 
Results of the in vitro test of A-HAp/Ch-PLGA on two different cell lines: regular MRC5 
human lung fibroblasts and A549 human lung carcinoma cells: a) viability and cytotoxicity 
estimated using the MTT assay and the dye exclusion test, respectively; b) cytotoxicity 
following the 48 h recovery period. Data points represent averages (n = 4) and the error bars 
represent standard deviations.
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Figure 7. 
Primary mouse lung fibroblasts interact with 1 mg/ml HAp/Ch-PLGA (A–D and I–L) and 
A-HAp/Ch-PLGA particles (E–H) with no cytotoxicity or repulsion. A–D) Primary mouse 
lung fibroblasts surround HAp/Ch-PLGA particles. E–H) Primary mouse lung fibroblasts 
surround androstane-loaded HAp/Ch-PLGA particles. I–L) Primary mouse lung fibroblasts 
endocytose HAp/Ch-PLGA particles. Rhodamine-phalloidin-stained f-actin (red), DAPI-
stained nucleus (blue), and auto-fluorescing HAp/Ch-PLGA and A-HAp/Ch-PLGA particles 
(green).
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